Despite the success of CD19 CAR-Ts, many technical and biological obstacles, such as toxicity, CAR-T cell dysfunction, and tumor heterogeneity and antigen loss, have limited the use of CAR-T therapy to treat other hematologic cancers and solid tumors [131]. The gene discussed is CD19; the disease is neoplasm.